Pharmacokinetics – Calculators, Tools, Etc.

Internal Medicine Sections Pharmacokinetics
GlobalRPh Pharmacokinetics, Pharmacodynamics and Therapeutic Drug Monitoring

Clinical Pharmacokinetics and Therapeutic Drug Monitoring Resource Center

Clinician-focused pharmacokinetic calculators, vancomycin AUC and Bayesian dosing, measured-level analysis, aminoglycoside dosing, renal-function assessment, therapeutic drug monitoring, cytochrome P450 and pharmacogenomic resources, patient-specific dosing concepts, and related clinical references.

Vancomycin AUC and Bayesian dosing Measured-level PK Renal function for dosing Internal Medicine Sections
Primary audience: physicians, pharmacists, nurses, advanced practice clinicians, pharmacometric reviewers, and other healthcare professionals involved in medication dosing, therapeutic drug monitoring, and individualized pharmacotherapy.

Clinical reference index

Pharmacokinetic clinical domains

Clinical framework

Pharmacokinetic dosing requires more than an equation

Patient-specific dosing integrates drug exposure, dose history, sampling time, distribution, clearance, renal and hepatic function, body size, critical illness, interacting medications, assay characteristics, treatment indication, therapeutic target, and the clinical trajectory. A mathematically correct equation can still produce a clinically misleading result if its assumptions do not match the patient or the input data.

We organize our pharmacokinetic resources by the question the clinician is trying to answer: selecting an initial regimen, interpreting one or more measured concentrations, estimating clearance, evaluating total exposure, managing a level obtained at an unexpected time, or assessing an interaction that may alter absorption, distribution, metabolism, or elimination.

Clearance Determines the relationship between dose rate and average systemic exposure.
Volume of distribution Links the amount of drug in the body with concentration and can change with illness and fluid status.
Elimination rate / half-life Influences dosing interval, accumulation, washout, and the timing of measured concentrations.
AUC / exposure Integrates concentration over time and can be more informative than a single concentration for selected drugs.
1. Confirm the clinical target Define the indication, therapeutic objective, toxicity concern, and evidence-supported target.
2. Confirm the data Verify dose history, infusion duration, sample time, current weight, renal trajectory, and assay units.
3. Select the method Use a method appropriate to the drug, available concentrations, patient population, and steady-state status.
4. Reassess clinically Interpret model output with response, toxicity, organ-function changes, and the next monitoring plan.
Pharmacokinetics Laboratory Illustration
Primary 2026 vancomycin decision-support platform

GlobalRPh Vancomycin Dosing and Bayesian AUC Calculator Advanced

We released the Advanced platform in August 2026 to integrate conventional first-order pharmacokinetics, two-level AUC estimation, empiric AUC-targeted dosing, Bayesian forecasting, five population-specific priors, clinician-selected regimen simulation, model-selection safeguards, and conventional fallback when Bayesian requirements are not satisfied.

The calculator is a beta clinical decision-support tool and requires clinician confirmation, accurate administration and sampling times, population-model review, and local validation before unrestricted clinical deployment.

Open the Advanced Vancomycin Calculator

Methods, equations and model documentation

Advanced Bayesian Technical Methods

The technical documentation describes the Bayesian mathematics, five population priors, renal-function calculations, model selection, parameter bounds, conventional fallback, concentration-time equations, data-quality requirements, validation status, worked examples, and clinical limitations.

Open Technical Methods

Return to top Internal Medicine Sections

Vancomycin pharmacokinetics

AUC-guided dosing, Bayesian forecasting, conventional PK, and regimen simulation

For serious MRSA infections, current multidisciplinary guidance favors AUC-guided monitoring rather than trough-only targeting. The evidence-supported AUC24/MIC target is generally 400 to 600 when a broth-microdilution MIC of 1 mg/L is assumed. Clinical extrapolation beyond that population and indication requires appropriate caution.

Current primary workflow

The 2026 Advanced calculator is our principal vancomycin PK platform because it supports model-informed Bayesian dosing as well as conventional AUC methods and explicit fallback logic.

Established conventional AUC workflow

Our existing empirical and advanced AUC calculators remain available for conventional first-order pharmacokinetic analysis and continuity with established hospital workflows.

2026 Advanced platform

Conventional AUC tools

Historical Bayesian beta resource

This older page contains a historical statement that GlobalRPh could not provide Bayesian vancomycin analysis. That statement predates the August 2026 Advanced platform and should not be used to characterize our current capabilities.
Vancomycin scope: AUC-guided dosing does not determine whether vancomycin is the appropriate antimicrobial. Results require interpretation with infection source, severity, microbiology, renal trajectory, nephrotoxin exposure, source control, patient population, local protocols, and clinical response.

Measured concentrations and patient-specific PK

Dosing by levels, non-steady-state analysis, and concentration-time interpretation

Measured concentrations are only as reliable as the underlying administration and collection times. Before fitting a pharmacokinetic model, clinicians should reconcile actual dose times, infusion duration, delayed or omitted doses, sampling times, line-draw contamination risk, and changes in renal function or fluid status.

Two-level pharmacokinetics

General PK foundations

Key interpretation variables

  • Actual administration time and infusion duration
  • Exact concentration collection time
  • Steady state versus non-steady state
  • One-compartment versus multi-compartment assumptions
  • Distribution-phase sampling
  • Renal trajectory and augmented renal clearance
  • Body weight, fluid balance, and critical illness
When concentration timing is uncertain, the correct response is not to force the level into a model. Reconstruct the medication administration record and specimen collection history before accepting patient-specific clearance or volume estimates.
Return to top Internal Medicine Sections

Aminoglycoside pharmacokinetics

Conventional dosing, extended-interval concepts, measured levels, and toxicity monitoring

Aminoglycoside dosing depends on indication, organism, dosing strategy, renal function, distribution volume, critical illness, obesity, age, and the specific therapeutic target. Nephrotoxicity and ototoxicity risk require deliberate monitoring rather than concentration interpretation in isolation.

GlobalRPh aminoglycoside calculators

Drug and administration references

Modernization priority

Our original aminoglycoside calculators contain important foundational PK logic but also rely heavily on older textbooks and target conventions. We plan to update conventional and extended- interval strategies, sampling interpretation, special populations, renal replacement therapy, toxicity monitoring, and current antimicrobial guidance.

Established vancomycin concentration tools

Single-level and trough-timing calculators retained for defined clinical questions

These tools remain useful for reconstructing a mistimed level, estimating concentration decay, reviewing an older workflow, or supporting selected non-AUC analyses. They should not be presented as the primary monitoring strategy for serious MRSA infections when AUC-guided monitoring is indicated.

Single-level analysis

Mistimed / supratherapeutic concentration tools

Clinical status

Many of these pages were built around trough-centered targets and older population equations. We retain them for continuity while updating their positioning, references, and warnings so their intended role is not confused with contemporary AUC-guided vancomycin monitoring.

Return to top Internal Medicine Sections

Kidney function for medication dosing

Creatinine clearance, race-free eGFR, cystatin C, unstable renal function, and pediatric assessment

Drug-dosing decisions may depend on the kidney-function method used in the clinical study or product labeling. Cockcroft-Gault creatinine clearance remains embedded in many drug labels and legacy dosing studies, while contemporary kidney-disease assessment increasingly uses race-free CKD-EPI equations. The method and units should therefore be matched to the clinical decision rather than treated as interchangeable.

Contemporary eGFR assessment

NIDDK identifies the 2021 CKD-EPI equations as the newest adult equations and recommends considering the combined creatinine-cystatin C equation when kidney-function estimates are close to a critical drug-dosing decision value.

Drug-label creatinine clearance

Many approved medication labels historically used measured CrCl or Cockcroft-Gault estimated CrCl. Clinicians should confirm which renal-function method the applicable label or dosing evidence requires.

Current external kidney-function references

GlobalRPh drug-dosing renal tools

Historical renal-equation pages

Important distinction: Our older CKD-EPI and MDRD pages include race coefficients that are not part of current 2021 CKD-EPI race-free assessment. Our pediatric calculator also states that Bedside Schwartz is the best pediatric method; current NIDDK resources now emphasize CKiD U25 equations for children, adolescents, and young adults. We have prioritized these pages for revision.

Therapeutic drug monitoring

Drug concentrations must be interpreted with timing, indication, protein binding, and clinical response

Therapeutic drug monitoring is most useful when a measured concentration addresses a specific clinical question. The same numerical concentration may have different implications depending on sampling time, free versus total concentration, organ function, indication, interacting drugs, adherence, toxicity, and whether the patient is at steady state.

GlobalRPh level references

Phenytoin

Our current phenytoin calculator relies primarily on older Michaelis-Menten and protein-binding references. We plan to update free-level interpretation, hypoalbuminemia, kidney dysfunction, drug interactions, genotype-informed therapy, and contemporary antiseizure-medication context.

Digoxin

Our current digoxin page displays a broad 0.5 to 2.0 ng/mL range and cites predominantly older literature. Contemporary HFrEF guidance uses lower serum concentration targets. We have prioritized this calculator for indication-specific and target-specific review.
A population therapeutic range is not a substitute for patient-specific interpretation. Toxicity can occur within a published range, and therapeutic response can occur outside it. Sampling time, assay methodology, free versus total concentration, protein binding, renal function, drug interactions, and clinical status must be considered.
Return to top Internal Medicine Sections

Drug metabolism, interactions, and pharmacogenomics

Cytochrome P450 pathways, transporters, interaction assessment, and genotype-informed therapy

Pharmacokinetic interactions can alter exposure through inhibition or induction of metabolic enzymes, changes in transport, altered absorption, organ-function effects, or changes in protein binding. Static interaction lists should therefore be verified against current labeling and authoritative interaction resources.

GlobalRPh CYP resource

Current FDA interaction resources

Pharmacogenomics

We plan to modernize our CYP tool using current FDA interaction examples, transporter information, contemporary labeling, and a clearer distinction between mechanistic interaction potential and clinically actionable exposure changes.

Special populations and altered pharmacokinetics

Obesity, critical illness, renal replacement therapy, pediatrics, pregnancy, aging, and unstable organ function

Population averages become less reliable when physiology differs substantially from the derivation cohort. Special populations require explicit review of the model used, the weight scalar, renal function, distribution assumptions, protein binding, extracorporeal clearance, and the availability of measured concentrations.

Body size and obesity

Critical illness / RRT / unstable renal function

Pediatrics / pregnancy / aging

Bayesian model-informed dosing is not automatically valid because Bayesian mathematics is being used. The population prior must be appropriate for the patient, the dosing and concentration history must be accurate, and the fitted result must remain clinically plausible. Unsupported populations require an alternative method or specialist pharmacometric review.
Return to top Internal Medicine Sections

GlobalRPh pharmacokinetics and TDM reading

Current articles relevant to exposure-guided and patient-specific pharmacotherapy

We surface current GlobalRPh reviews that intersect directly with pharmacokinetics, therapeutic drug monitoring, antimicrobial exposure, toxicity, precision dosing, and pharmacogenomics.

2026

GlobalRPh Vancomycin Dosing and Bayesian AUC Advanced Calculator Bayesian forecasting | Five population models | Conventional AUC | Model safeguards Vancomycin for MRSA: Reassessing the Standard in 2026 AUC-guided monitoring | Resistance | Nephrotoxicity | Alternative therapy Precision Epilepsy and Gene-Targeted Therapy Therapeutic drug monitoring | Pharmacogenomics | Antiseizure therapy Cefepime Neurotoxicity: Exposure, Renal Function, and Clinical Risk Renal dosing | Exposure-toxicity relationship | TDM limitations Pan-Resistant Gram-Negatives and Dosing Optimization Aminoglycosides | PK optimization | Toxicity | Resistant infection Colistin and Fosfomycin: Pharmacologic Reassessment Exposure | Therapeutic monitoring | Toxicity | Resistant organisms
Pharmacokinetics Calculator Archive Infectious Disease Articles GlobalRPh Video Library

GlobalRPh pharmacokinetics video

Vancomycin dosing and therapeutic drug monitoring

Our current pharmacokinetics video introduces vancomycin dosing and therapeutic drug monitoring. The section should expand to include AUC-guided dosing, Bayesian model interpretation, level timing, renal-function method selection, and measured-level pharmacokinetics.

Existing video

Vancomycin Dosing and Therapeutic Drug Monitoring Explained

Open the GlobalRPh Video Library

Priority video topics

  • AUC-guided vancomycin monitoring: 400 to 600 and what the target means
  • Bayesian priors, posteriors, shrinkage, and model selection
  • One level versus two levels for Bayesian AUC estimation
  • Conventional first-order AUC calculations
  • How mistimed levels affect PK estimates
  • Cockcroft-Gault versus 2021 CKD-EPI for medication decisions
  • Phenytoin free versus total concentration interpretation
  • Aminoglycoside concentration monitoring and special populations
Return to top Internal Medicine Sections

Clinical content modernization

Priority updates within the GlobalRPh Pharmacokinetics library

Pharmacokinetics is one of our longest-standing clinical resource areas. Many calculations remain mathematically useful, but the evidence framework surrounding vancomycin monitoring, kidney-function estimation, therapeutic targets, pharmacogenomics, and drug interactions has changed substantially. We are preserving useful computational logic while updating clinical interpretation and evidence status.

Priority resource reviews

  • Earlier Vancomycin Bayesian Beta Page: replace the historical statement that GlobalRPh cannot provide Bayesian analysis with a clear redirect to our August 2026 Advanced platform and retain the earlier page only when needed for historical comparison.
  • Vancomycin AUC Calculator Suite: harmonize terminology, AUC targets, infusion assumptions, concentration timing, renal-function inputs, obesity handling, special-population cautions, and cross-links so users can immediately distinguish the 2026 Advanced platform from established conventional tools.
  • Advanced Pharmacokinetics 2010-2011 and 2019 Calculators: preserve their useful first-order equations and aminoglycoside workflows while replacing claims that older textbooks represent the most recent pharmacokinetic evidence.
  • Vancomycin Single-Level and Trough Tools: retain them for mistimed levels, historical analysis, and defined concentration questions while explicitly separating them from the current AUC-guided pathway for serious MRSA infection.
  • Aminoglycoside Dosing: update target strategies, extended-interval dosing, sampling interpretation, obesity, renal dysfunction, dialysis/RRT, cystic fibrosis, critical illness, ototoxicity, nephrotoxicity, and antimicrobial-stewardship context.
  • Adult Kidney-Function Tools: retain Cockcroft-Gault when required by medication labeling while adding 2021 CKD-EPI race-free equations, cystatin C options, de-indexed eGFR considerations, and clearer guidance when the estimate lies near a dosing threshold.
  • Historical Race-Based CKD-EPI / MDRD Pages: relabel them as historical equations and remove language that could imply they represent current preferred kidney-function assessment.
  • Pediatric Creatinine Clearance: revise the page around current CKiD U25 equations and clearly distinguish pediatric eGFR from measured clearance and older Schwartz-era formulas.
  • Unstable Renal Function: review the mathematical approach and add stronger warnings regarding rapidly changing creatinine, urine output, kinetic eGFR concepts, renal replacement therapy, and the limitations of steady-state equations.
  • Digoxin Dosing Calculator: update indication-specific dosing, contemporary HFrEF serum concentration targets, renal function, lean body mass, drug interactions, toxicity interpretation, and current guideline positioning.
  • Phenytoin Dosing Calculator: update nonlinear kinetics, free versus total levels, hypoalbuminemia, kidney dysfunction, enteral feeding, interactions, CYP2C9 / HLA-B pharmacogenomics, and current antiseizure-medication practice.
  • Therapeutic Drug Levels: systematically verify current therapeutic ranges, sampling times, free-level indications, toxicity thresholds, assay considerations, and indication-specific interpretation for each monitored medication.
  • Cytochrome P450 Analysis Tool: rebuild using current FDA CYP and transporter examples, current labeling, clinically actionable interaction magnitude, transporter pathways, and contemporary pharmacogenomic cross-links.
  • General Pharmacokinetic Overview: update first-order, nonlinear, multi-compartment, AUC, accumulation, steady state, loading-dose, maintenance-dose, and TDM explanations using a formal clinician-facing framework and contemporary references.
  • Warfarin and Heparin Cross-Links: move protocol-level anticoagulation content toward current Cardiology/Hematology pathways while retaining Pharmacokinetics links only where therapeutic monitoring or pharmacogenomics is directly relevant.
PK method selector Guide users toward Bayesian, conventional two-level, single-level, or population-based approaches based on available data.
Renal-function decision layer Display the equation, indexing status, body-weight assumption, and drug-label compatibility before dose recommendations.
TDM timing validator Check dose and level timestamps before calculating patient-specific pharmacokinetic parameters.
Free-level interpretation Improve phenytoin and other protein-bound drug workflows when total concentrations may be misleading.
Aminoglycoside 2.0 Modern conventional and extended-interval dosing with patient-specific monitoring and toxicity safeguards.
CYP / transporter 2.0 Integrate current FDA interaction classifications, transporters, labeling, and CPIC genotype-informed pathways.

Current external standards

Authoritative pharmacokinetic, renal-function, interaction, and pharmacogenomic references

We provide direct access to current professional and federal resources because the clinical framework surrounding a pharmacokinetic calculation may change even when the underlying equation does not.

ASHP / IDSA / PIDS / SIDP Vancomycin Monitoring Consensus Guideline Current multidisciplinary reference for AUC-guided vancomycin monitoring in serious MRSA infection, including the generally recommended AUC24/MIC target of 400 to 600 when MIC is assumed to be 1 mg/L by broth microdilution. Open Vancomycin Guideline
NIDDK Drug Dosing in Adults With CKD Discusses contemporary kidney-function estimation for medication dosing, including 2021 CKD-EPI and use of combined creatinine-cystatin C when a decision lies near a dosing cutoff. Open NIDDK Drug-Dosing Resource
NIDDK Adult eGFR Equations Current race-free adult eGFR equations and discussion of creatinine, cystatin C, and critical decision values. Open Adult eGFR Resource
NIDDK CKiD U25 Pediatric / Young Adult eGFR Current pediatric and young-adult kidney-function equations, including combined creatinine-cystatin C assessment. Open CKiD U25 Resource
FDA CYP and Transporter Interaction Examples for Healthcare Professionals Current federal resource for clinically relevant examples of CYP substrates, inhibitors, inducers, and transporter-mediated interactions. Open FDA Interaction Examples
FDA Drug Development and Drug Interactions Tables Reference tables for metabolic enzymes and transporters, including substrates, inhibitors, and inducers. Open FDA Interaction Tables
CPIC Pharmacogenomic Guidelines Clinical guidance for using available genetic test results to optimize drug therapy for supported gene-drug pairs. Open CPIC Guidelines
AHA / ACC / HFSA Heart Failure Guideline Current cardiovascular guideline context for digoxin use and lower serum digoxin concentration targets in HFrEF. Open Heart Failure Guideline Hub

Supporting GlobalRPh clinical resources

Drug information, renal dosing, infectious disease, critical care, pediatrics, and clinical calculators

Medication and laboratory support

Related specialty portals

Calculator and site directories

Rationale for retaining established pharmacokinetic calculators

Many GlobalRPh pharmacokinetic calculators remain mathematically useful and are embedded in longstanding hospital, educational, and clinical workflows. We are retaining those tools while modernizing the evidence framework, therapeutic targets, renal-function methods, special-population assumptions, pharmacogenomic context, and clinical warnings that surround the calculations.

Return to top Internal Medicine Sections

Clinical use: Our pharmacokinetic calculators, Bayesian models, population equations, therapeutic drug-level references, renal-function tools, and clinical articles are intended to support, not replace, current product labeling, current professional guidance, institutional protocols, local validation, accurate medication-administration and specimen-collection records, specialist consultation when indicated, and independent professional judgment. Model output should be interpreted as an estimate, not as an autonomous medication order.

Return to Internal Medicine Sections  |  Advanced Vancomycin AUC Calculator  |  Therapeutic Drug Levels  |  Renal Dosing  |  Infectious Disease

Return to the top of the Pharmacokinetics page

Alphabetical Listing of individual drugs

abcdefghijklm
nopqrstuvwxyz

Common LAB Values  Renal Dosing

Internal Medicine Sections